Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 3Genitourinary 2Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 11Prostatic Neoplasms 2Neoplasm Metastasis 2Melanoma 2Kidney Neoplasms 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Neoplasms 1

Interventions

Docetaxel 35pembrolizumab 32Nivolumab 27enzalutamide 20Prednisone 20Sunitinib 16Cyclophosphamide 16aldesleukin 14Zoledronic Acid 13Interleukin-2 13Gemcitabine 13Bevacizumab 13Specimen Handling 12Ipilimumab 12Radiosurgery 11Everolimus 11Androgen Antagonists 11Abiraterone Acetate 11fludarabine 10Sorafenib 10Radiotherapy 10Paclitaxel 10Magnetic Resonance Spectroscopy 10pazopanib 9abiraterone 9Doxorubicin 8Carboplatin 8Biopsy 8avelumab 7temsirolimus 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Introns × Genitourinary × Clear all
NCT00293527 2013-05-23

Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma

Ohio State University Comprehensive Cancer Center

Phase 2 Withdrawn
Genitourinary

Kidney Neoplasms, Neoplasm Metastasis

NCT00485563 2012-03-08

A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma

Endocyte

Phase 2 Terminated
12 enrolled
Genitourinary

Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡